Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 609

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 609
---
 RPA Closing Payment, which amount extinguished and reduced $2.5 million of the outstanding balance under the Oramed Note. The ZTlido Royalty Purchase Agreement terminates six months following receipt by the ZTlido RPA Purchasers of all payments of the ZTlido Purchased Receivables to which each ZTlido RPA Purchaser is entitled during the period commencing on the closing date of the ZTlido Royalty Purchase Agreement and expiring on the tenth anniversary of such closing date. The Company elected the fair value option for the ZTlido Royalty Purchase Agreement and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of September 30, 2025 and December 31, 2024, the fair value of the ZTlido Royalty Purchase Agreement was $14.3 million and $6.8 million, respectively, recorded as a purchased revenue liability on the consolidated balance sheets. The Company incurred $0.2 million of issuance costs in connection with the ZTlido Royalty Purchase Agreement, which were included in the consolidated statement of operations for the year ended December 31, 2024. The following table summarizes the purchased revenue liability activity related to ZTlido Royalty Purchase Agreement (in thousands):

| Ending Balance as of December 31, 2024              |     | September 30, 
 2025          |  6,800 |   |
|:----------------------------------------------------|:----|:--------------|-------:|:--|
| Repayment of purchased revenue liability            |     |               | (2,333 | ) |
| Change in fair value of purchased revenue liability |     |               |  9,833 |   |
| Ending Balance as of September 30, 2025             |     | $             | 14,300 |   |

F-89

Gloperba-Elyxyb Royalty Purchase Agreement On February 28, 2025 (the “Gloperba-Elyxyb Closing Date”), the Company entered into the Gloperba-Elyxyb Royalty Purchase Agreement with certain institutional investors (collectively, the “Gloperba-Elyxyb Royalty Investors”) and Oramed (together with the Gloperba-Elyxyb Royalty Investors, the “Gloperba-Elyxyb RPA Purchasers”). Pursuant to the